The scientists of the world ask to take into account several innovations that will have repercussions in the solution of humanity’s problems.
According to the magazine Naturecited by the Infomed website, the development of vaccines should be observed, taking into account the successful deployment of mRNA immunogens during the COVID-19 pandemic, because there are a large number of them in development to treat other diseases.
BioNTech in Mainz, Germany is expected to start the first human trials of mRNA vaccines against malaria, tuberculosis and genital herpes in the coming weeks. BioNTech is also collaborating with New York City-based Pfizer to test an mRNA-based candidate for reducing the rate of shingles. Moderna in Cambridge, Massachusetts, also has mRNA vaccine candidates for the viruses that cause genital herpes and shingles, the publication notes.
In addition, it is worth noting the obtaining of combined vaccines from the BioNTech and Pfizer laboratories, designed to protect against both COVID-19 and influenza. They contain mRNA strands encoding binding proteins for SARS-CoV-2, Omicron BA.4/BA.5, and four influenza variants.
Acknowledges that the World Health Organization publishes a revised list of priority pathogens, reviewed by some 300 scientists in more than 25 viral and bacterial families to identify pathogens that could cause future outbreaks.
In addition, the first approval of a CRISPR gene-editing therapy could be disclosed in 2023, following promising results from clinical trials using the CRISPR-Cas9 system to treat thalassemia and sickle cell disease, two genetic blood disorders.